[The Total Costs of Owning, Trading ETFs]. That allows investors to claim tax losses on the property even when they’re putting money in their pockets.“You want to show as much losses as you possibly can for your deductions,” said Papamarkou’s Perkin. Ehlers-Danlos Syndrome (EDS) is a group of hereditary disorders of connective tissue. Benzinga does not provide investment advice. ACER is pursuing BARDA and Gates Foundation funding for the program. Based on the solid progress of its pipeline, the firm has high hopes for this healthcare name.Representing Oppenheimer, analyst Justin Kim points out that he came away from a recent conversation with the CEO even more confident in ALDX’s long-term growth prospects. An Amazon.com, Inc (NASDAQ: AMZN) senior manager and her two family members were charged with insider trading by the United States Securities and Exchange Commission on Monday.What Happened: Laksha Bohra is alleged to have tipped her husband Viky Bohra about highly confidential information about the e-commerce giant's financial performance between January 2016 and July 2018, the SEC said in a statement.According to SEC, the Amazon manager came into possession of the information as she prepared and reviewed earnings calculations used to finalize numbers for the retailer's quarterly and annual earnings filed with the regulator.The SEC's complaint, filed in a federal court in Seattle, states that Viky Bohra and his father Gotham Bohra used the information to trade using 11 separate accounts maintained by different members of the family.The family allegedly reaped benefits to the tune of $1.4 million from the unlawful trading.The Bohras have agreed to return nearly $1.5 million they gained in illegal profit and pay an additional penalty of $1,106,399, as per the SEC.The U.S. Attorney's Office for the Western District of Washington filed criminal charges against Viky Bohra on Monday.Why It Matters: The Jeff Bezos-led company reportedly terminated Bohra in 2018 for reasons not mentioned in the complaint, Fortune reported. Veteran Michael Gelchie will become chief executive officer later this week -- the seventh CEO appointed by Dreyfus in eight years -- replacing Ian McIntosh.Despite its recent travails, the first half of 2020 showed some improvement for LDC. But he need not taketh away. “Despite some volatility in the shares, we see a solid setup emerging as the company initiates its Phase 3 RASP studies in dry eye disease (DED),” he said.Speaking to the potential of RASP as an accepted dry eye endpoint, ALDX has experienced “a watershed moment,” with it facilitating an expedited path to registration (from traditional sign endpoints) and greater likelihood of clinical trial success, based on reproxalap's mechanism of action (MoA) as a RASP-trap, according to Kim.He added, “Moreover, agreement on RASP could have broader implications for a commercial launch in dry eye, a market that we believe will see segmentation as more therapies with targeted MoAs become incorporated into the armamentarium.”“We continue to be impressed by the progress in achieving a potential concurrent filing for dry eye and allergic conjunctivitis (AC), appreciating the importance of a differentiated dry eye agent with action also in AC.